K67 Stock Overview
A contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide.
Snowflake Score | |
---|---|
Valuation | 5/6 |
Future Growth | 3/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Fortrea Holdings Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$21.00 |
52 Week High | US$36.60 |
52 Week Low | US$20.60 |
Beta | 0 |
11 Month Change | -7.08% |
3 Month Change | -42.31% |
1 Year Change | n/a |
33 Year Change | n/a |
5 Year Change | n/a |
Change since IPO | -28.57% |
Recent News & Updates
Recent updates
Shareholder Returns
K67 | DE Life Sciences | DE Market | |
---|---|---|---|
7D | -4.5% | -0.5% | 0.09% |
1Y | n/a | -14.4% | 3.1% |
Return vs Industry: Insufficient data to determine how K67 performed against the German Life Sciences industry.
Return vs Market: Insufficient data to determine how K67 performed against the German Market.
Price Volatility
K67 volatility | |
---|---|
K67 Average Weekly Movement | 8.0% |
Life Sciences Industry Average Movement | 6.1% |
Market Average Movement | 4.8% |
10% most volatile stocks in DE Market | 10.7% |
10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: K67's share price has been volatile over the past 3 months.
Volatility Over Time: K67's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
2023 | 16,000 | Tom Pike | www.fortrea.com |
Fortrea Holdings Inc., a contract research organization, primarily engages in the provision of biopharmaceutical product and medical device development services worldwide. The company operates through two segments: Clinical Services and Enabling Services. The Clinical Services segment provides across the clinical pharmacology and clinical development spectrum.
Fortrea Holdings Inc. Fundamentals Summary
K67 fundamental statistics | |
---|---|
Market cap | €1.91b |
Earnings (TTM) | -€85.17m |
Revenue (TTM) | €2.87b |
0.7x
P/S Ratio-22.4x
P/E RatioIs K67 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
K67 income statement (TTM) | |
---|---|
Revenue | US$3.08b |
Cost of Revenue | US$2.60b |
Gross Profit | US$475.90m |
Other Expenses | US$567.10m |
Earnings | -US$91.20m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
Earnings per share (EPS) | -1.02 |
Gross Margin | 15.47% |
Net Profit Margin | -2.96% |
Debt/Equity Ratio | 101.5% |
How did K67 perform over the long term?
See historical performance and comparison